Nutriband Signs Commercial Development And Clinical Supply Agreement With Kindeva Drug Delivery For Aversa Fentanyl, An Abuse Deterrent Fentanyl Patch
Portfolio Pulse from Benzinga Newsdesk
Nutriband Inc. has signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for Aversa Fentanyl, an abuse-deterrent fentanyl patch. This agreement will enable Kindeva to develop the manufacturing process and produce clinical supplies for FDA-required studies. Aversa Fentanyl, which combines Nutriband's proprietary technology with Kindeva's FDA-approved patch system, has a potential market of $80M - $200M in annual US sales. The technology aims to improve safety while ensuring access for patients in need.
January 05, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nutriband Inc. has entered into a significant agreement with Kindeva to advance Aversa Fentanyl, which could lead to substantial market potential and revenue growth.
The agreement with Kindeva is a critical step towards commercializing Aversa Fentanyl, which is expected to have a strong market potential. This partnership is likely to be viewed positively by investors, as it progresses Nutriband's lead product towards market readiness and potential revenue generation. The estimated market potential of $80M - $200M in annual US sales underscores the financial significance of this development.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100